Causative glaucoma treatment: promising targets and delivery systems.
Journal
Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
10
12
2018
revised:
13
02
2019
accepted:
15
03
2019
pubmed:
25
3
2019
medline:
12
5
2020
entrez:
26
3
2019
Statut:
ppublish
Résumé
Glaucoma is one of the most common causes of blindness worldwide. Elevated intraocular pressure (IOP) is the major modifiable risk factor of the disease. Conventional therapy suffers from poor compliance, low bioavailability, and the lack of causative treatment options. To improve therapeutic success, it is crucial to identify major mediators of pathological changes associated with elevated IOP and to intervene at the molecular level. Here, we discuss relevant key functions of transforming growth factor-β2 (TGF-β2), connective tissue growth factor (CTGF), integrins, Rho-associated kinase (ROCK), and nitric oxide (NO) with regard to the onset of glaucoma, highlighting new drug delivery approaches for causative treatment.
Identifiants
pubmed: 30905679
pii: S1359-6446(18)30403-3
doi: 10.1016/j.drudis.2019.03.017
pii:
doi:
Substances chimiques
Transforming Growth Factor beta2
0
Nitric Oxide
31C4KY9ESH
rho-Associated Kinases
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1606-1613Informations de copyright
Copyright © 2019. Published by Elsevier Ltd.